Survivorship Programs for the Cancer Survivor: Next steps for the Modern Cancer Patient

Main Article Content

Jonathan Glanzman, MD Kara Banson, BA John G. Roubil, BA Lakshmi Shanmugham, MD Beth Herrick, MD David Goff, MD Jesse Aronowitz, MD Daniel Han, MD Eric Ko, MD, PhD Shirin Sioshansi, MD M. Giulia Cicchetti, MD Paul Rava, MD, PhD Allison Sacher, MD Linda Ding, PhD Carla Bradford, PhD Abdulnasser Khalifeh, PhD I-Lin Kuo, PhD Yankhua Fan, PhD Suhong Yu, PhD Harry Bushe, MS Jonathan Saleeby, MD Fenghong Liu, PhD Camelia Bunaciu, MSc Maryann Bishop-Jodoin, MEd Thomas J. FitzGerald, MD

Abstract

Cancer remains a significant medical challenge for modern health care. Therapies have improved. Chemotherapy can now be applied and targeted to specific expression products and biomarkers. Radiation therapy is directed to specific targets with applied image guidance including less normal tissue in the treatment fields. Surgery has improved with robotics and improvements in rehabilitation and recovery. More patients are surviving their primary challenge from malignancy. As such, more patients now have the imprint of therapy upon their normal tissues. It is important for all practitioners, including primary care physicians and medical subspecialists, to participate in the aftercare of these patients with a comprehensive strategic manner to both prevent normal tissue injury and ameliorate injury if/when it occurs.

Downloads

Download data is not yet available.

Article Details

How to Cite
GLANZMAN, Jonathan et al. Survivorship Programs for the Cancer Survivor: Next steps for the Modern Cancer Patient. Medical Research Archives, [S.l.], v. 9, n. 7, july 2021. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/2490>. Date accessed: 19 may 2022. doi: https://doi.org/10.18103/mra.v9i7.2490.
Section
Research Articles

References

1. Bentzen SM, Constine LS, Deasy JO, et al. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S3-9.

2. Marks LB, Yorke ED, Jackson A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S10-9.

3. Lin J, Lv X, Niu M, et al. Radiation-induced abnormal cortical thickness in patients with nasopharyngeal carcinoma after radiotherapy. NeuroImage Clin. 2017;14:610-621.

4. Ding Z, Zhang H, Lv X-F, et al. Radiation-induced brain structural and functional abnormalities in presymptomatic phase and outcome prediction. Hum Brain Mapp. 2018;39(1):407-427.

5. Withers HR, Taylor JM, Maciejewski B. Treatment volume and tissue tolerance. Int J Radiat Oncol Biol Phys. 1988;14(4):751-759.

6. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21(1):109-122.

7. Marks LB, Munley MT, Spencer DP, et al. Quantification of radiation-induced regional lung injury with perfusion imaging. Int J Radiat Oncol Biol Phys. 1997;38(2):399-409.

8. Kwa SL, Lebesque JV, Theuws JC, et al. Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys. 1998;42(1):1-9.

9. Graham MV. Predicting radiation response. Int J Radiat Oncol Biol Phys. 1997;39(3):561-562.

10. Graham MV, Purdy JA, Emami B, et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 1999;45(2):323-329.

11. Hanania AN, Mainwaring W, Ghebre YT, Hanania NA, Ludwig M. Radiation-induced lung injury: Assessment and management. Chest. 2019;156(1):150-162.

12. Käsmann L, Dietrich A, Staab-Weijnitz CA, et al. Radiation-induced lung toxicity - cellular and molecular mechanisms of pathogenesis, management, and literature review. Radiat Oncol. 2020;15(1):214.

13. Yusuf SW, Venkatesulu BP, Mahadevan LS, Krishnan S. Radiation-induced cardiovascular disease: A clinical perspective. Front Cardiovasc Med. 2017;4. doi:10.3389/fcvm.2017.00066

14. Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368(11):987-998.

15. Dawson LA, McGinn CJ, Normolle D, et al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol. 2000;18(11):2210-2218.

16. Dawson LA, Ten Haken RK, Lawrence TS. Partial irradiation of the liver. Semin Radiat Oncol. 2001;11(3):240-246.

17. Baradaran-Ghahfarokhi M. Radiation-induced kidney injury. J Renal Inj Prev. 2012;1(2):49-50.

18. Oh D, Huh SJ. Insufficiency fracture after radiation therapy. Radiat Oncol J. 2014;32(4):213-220.

19. Lukez A, O’Loughlin L, Bodla M, Baima J, Moni J. Positioning of port films for radiation: variability is present. Med Oncol. 2018;35(5):77.

Most read articles by the same author(s)